Epic Bio to Present at the Upcoming CRISPR2.0 Conference
November 21, 2023 12:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
November 16, 2023 06:00 ET
|
Epic Bio
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root...
Genome Editing Market revenue to hit USD 69.6 Billion by 2036, says Research Nester
November 14, 2023 05:30 ET
|
Research Nester
New York, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The global genome editing market size is slated to expand at ~21.1% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 69.6...
Epic Bio to Participate in Upcoming Investor Conference
November 07, 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
October 26, 2023 11:09 ET
|
Epic Bio
Epic Bio presented new details on an in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas known to work in human cells.
World-Leading Gene Editing Technology Unveiled in United Kingdom
October 23, 2023 12:38 ET
|
Research and Markets
Dublin, Oct. 23, 2023 (GLOBE NEWSWIRE) -- In a momentous stride toward the future of agriculture, scientists have recently achieved a remarkable breakthrough in the realm of gene editing. The...
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
October 19, 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
October 17, 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
US Gene Editing Market Poised for Unprecedented Growth: Rice University's Breakthrough Technology Shines
October 10, 2023 10:08 ET
|
Research and Markets
Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- In the midst of remarkable discoveries in gene editing, researchers at Rice University have unveiled a groundbreaking improvement to traditional CRISPR...
Epic Bio to Present at the Upcoming BMO Life Sciences Private Company Showcase
October 05, 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...